Design Therapeutics (DSGN) Change in Accured Expenses (2020 - 2026)

Design Therapeutics has reported Change in Accured Expenses for 7 years, with the latest figure at $955000.0 in Q2 2026.

• Change in Accured Expenses for Q2 2026 came in at $955000.0, up 76.2% year-over-year; the trailing twelve-month figure through Jun 2026 was $2.7 million (up 18.72% YoY), and the FY2025 annual result was $4.5 million, up 468.01% from the prior year.
• Change in Accured Expenses rose to $955000.0 in Q2 2026, from -$2.5 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $3.2 million in Q3 2022 and troughed at -$2.8 million in Q4 2023.
• A 5-year average of $325833.3 and a median of $482500.0 in 2022 frame the typical range for Change in Accured Expenses.
• The widest annual swing landed in 2022, when Change in Accured Expenses surged 1726.92%; it then plunged 911.63% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at $423000.0 in 2022, then tumbled by 764.3% to -$2.8 million in 2023, then soared by 135.84% to $1.0 million in 2024, then surged by 82.72% to $1.8 million in 2025, then plunged by 48.1% to $955000.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $955000.0 in Q2 2026, -$2.5 million in Q1 2026, and $1.8 million in Q4 2025.